From Podium To Practice – Breast Cancer ESMO Part 6
In this discussion, Dr. Wassim Mchayleh and Dr. Sara Tolaney dissect the efficacy signals from ASCENT-03 and TROPION-Breast02, including differences in objective response rate, 12-month OS, and median PFS. They highlight how early relapsers, brain metastases, and PD-L1 distribution contribute to performance gaps between trials. The conversation also addresses the ethical basis for crossover in ASCENT-03—driven by proven OS benefit with sacituzumab govitecan—and why dato-DXd did not incorporate crossover due to the absence of prior survival data. Sponsored By Gilead